Novartis

Novartis Q3 operating income up 6% on new drug sales

Third-quarter operating income, adjusted for special items, rose to US$5.46 billion

Novartis, which focuses on heart, kidney and metabolic drugs, immunology, neuroscience and oncology, is looking to boost its portfolio.

Novartis agrees to buy Avidity in US$12 billion biotech deal

The full deal is expected to close in the first half of 2026, subject to the completion of the separation

The company's strategy towards becoming carbon neutral involves reducing its energy consumption, and ensuring clean supply solutions from renewable energy sources.

Novartis Singapore steps up in the race to net zero

As part of its plans, it has implemented on-site solar panels, is purchasing all its electricity from renewable source, and exploring green heat technologies

The Swiss drugmaker will pay US$48 per share in cash for the New York-based biotech, which is developing a promising treatment to reduce systemic inflammation, a major driver of cardiovascular disease. 

Novartis to buy US biotech Tourmaline Bio for US$1.4 billion

Novartis is on the hunt for acquisitions that could boost its sales beyond 2025

Novartis joins a growing number of multinational drug companies to announce investments in the US this year.

Novartis pledges US$23 billion US investment as tariffs loom

Trump has repeatedly said he intends to impose tariffs on pharmaceuticals, citing the industry’s reliance on manufacturing sites around the world to supply the US market

“With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients,” says Bill Meury, CEO at Anthos.

Novartis to acquire Anthos for up to US$3.1 billion

The transaction will cost Novartis US$925 million upfront with potential additional payment of up to US$2.15 billion

The deal by Novartis also includes US$750 million of potential further payments upon achieving certain milestones.

Novartis to buy radiology specialist Mariana Oncology for US$1 billion

Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies to treat cancers

At the groundbreaking ceremony on Friday, DPM Heng Swee Keat said that the site expansion would more than double Novartis’ production capacity here.

Novartis invests US$256 million to expand Singapore plant

SWISS biopharma giant Novartis has invested US$256 million to expand its biopharmaceutical manufacturing plant in Singapore. The expanded site will focus on manufacturing therapeutic antibody drugs.

Novartis will offer shareholders 68 euros per share in cash and take MorphoSys private after the deal.

Novartis to acquire cancer-focused MorphoSys for 2.7 billion euros

DRUGMAKER Novartis said it will acquire MorphoSys, a developer of cancer treatments, for 2.7 billion euros (S$3.9 billion), adding a promising rare bone-marrow cancer treatment candidate to its portfo...

Novartis will also gain access to Voyager’s platform for discovery and development of potential gene therapies for treating spinal muscular atrophy.

Novartis signs gene therapy deal with Voyager for US$100 million upfront

Voyager Therapeutics said on Tuesday (Jan 2) Swiss-based drugmaker Novartis would pay US$100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.